7 drug makers in the headlines

Here are seven drugmakers that made headlines in the past week.

1. FDA calls out EpiPen manufacturer for product flaws linked to patient deaths
Meridian Medical Technologies, a Pfizer subsidiary that manufacturers EpiPen's for Mylan, is in hot water for failing to adequately investigate complaints about the auto-injectors' efficacy.

2. Genentech recalls clot-busting drug: 5 things to know
Genentech recalled its clot-busting drug Activase due to sterility issues.

3. Hemophilia drug trial halted after patient death: 3 things to know
Alnylam Pharmaceuticals stopped treating patients with its experimental drug fitusiran following the death of a clinical trial participant.

4. Eli Lilly to trim 8% of workforce: 4 things to know
Eli Lilly and Co. will lay off about 8 percent of its employees to cut costs in 2018.

5. Novo Nordisk settles diabetes drug lawsuit for $58.7M: 3 things to know
Novo Nordisk will pay nearly $58.7 million to settle a civil lawsuit claiming the company's sales team failed to share accurate information about health risks associated with the diabetes drug Victoza.

6. Patient death spurs FDA to halt cancer drug trials
The Food and Drug Administration placed a clinical hold on two of Collectis' clinical trials for an immunotherapy drug after a patient's death.

7. Hospira recalls 2 drugs over sterility issues: 4 things to know
Hospira recalled one lot of Hydromorphone, a pain medication, and four lots of the blood pressure drug Levophed due to a potential lack of sterility assurance. 

More articles on supply chain:

FDA calls out EpiPen manufacturer for product flaws linked to patient deaths
Facebook promotes 'clinical trials strategy' to drugmakers
CMS to replace beneficiary-owned medical equipment damaged by Harvey

Copyright © 2022 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Learning Opportunities

Featured Whitepapers

Featured Webinars